SFBC International Files Registration Statement for Public Equity Offe

    Business Editors/Health Editors

    MIAMI--(BUSINESS WIRE)--Feb. 8, 2005--SFBC International, Inc. (NASDAQ:SFCC), a provider of drug development services to branded pharmaceutical, biotechnology, generic drug and medical device companies, announced today that it has filed a registration statement on Form S-3 with the Securities and Exchange Commission relating to a proposed public offering of 3,500,000 shares of its common stock. 3,102,000 shares are being offered by SFBC International, Inc. (SFBC) and 398,000 shares are being offered by certain of its executive officers. In addition, SFBC intends to grant to the underwriters an option to purchase up to an additional 525,000 shares of common stock to cover over-allotments, if any.
    UBS Investment Bank will act as sole book-running manager for the proposed offering. Jefferies & Company, Inc. will act as co-manager. When available, copies of the preliminary prospectus relating to this offering may be obtained from UBS Investment Bank, Prospectus Department, 299 Park Avenue, New York, NY 10171.
    SFBC expects to use the proceeds of the proposed offering to repay $70 million of its outstanding term loan under its credit facility, for possible acquisitions and for general corporate purposes, including funding the continued growth and development of its business and working capital requirements.
    A registration statement relating to these securities has been filed with the Securities and Exchange Commission, but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

    About SFBC International, Inc.

    SFBC International, Inc. provides early and late stage clinical drug development services to branded pharmaceutical, biotechnology, generic drug and medical device companies around the world. The company has more than 30 offices located in North America, Europe, South America, India, and Australia. In early clinical development services, SFBC specializes primarily in the areas of Phase I and early Phase II clinical trials and bioanalytical laboratory services, including early clinical pharmacology. The company also provides late stage clinical development services globally that focus on Phase II through IV clinical trials. The company also offers a range of complementary services, including data management and biostatistics, clinical laboratory services, medical and scientific affairs, regulatory affairs and submissions, and clinical IT solutions. Additional information is available at the company's website, http://www.sfbci.com.
    Please note that this press release contains forward-looking statements that represent SFBC's current expectations and beliefs. These forward-looking statements are subject to risks and uncertainties, including: the registration statement may not be declared effective; the sale of shares may not be pursued because of business, economic or market conditions; and the proposed offering may not be consummated as anticipated.

--30--CM/mi*

CONTACT: SFBC International, Inc., Miami Ana Lopez, 305-895-0304 or Financial Dynamics Evan Smith, CFA / Erica Pettit, 212-850-5606 / 212-850-5614

KEYWORD: FLORIDA INDUSTRY KEYWORD: MEDICAL PHARMACEUTICAL BIOTECHNOLOGY SOURCE: SFBC International, Inc.

Copyright Business Wire 2005